Shanghai United Imaging Healthcare Co., Ltd. (688271)

Equity Research Report　|　Industry: High-end medical equipment manufacturing, medical imaging and radiotherapy equipment　|　Report date: September 13, 2026　|　As of the September 11, 2026 close; technical indicators, fund flows and market data primarily use that date as the cutoff, top-10 tradable shareholders as of March 31, 2026, and shareholder count as of June 30, 2026

This report was automatically compiled by AI based on publicly available information and is for reference only. It does not constitute investment advice.

1. Executive Summary

United Imaging Healthcare delivered “revenue growth with profit pressure” in the first half of 2026: operating revenue reached RMB 7.052 billion, up 17.22% year on year; net profit attributable to the parent was RMB 897 million, down 10.12%; and non-GAAP net profit attributable to the parent was RMB 827 million, down 14.38%. Net cash flow from operating activities was negative RMB 242 million. Profit pressure was mainly attributable to approximately RMB 118 million in foreign-exchange losses and increased investment in global operations, R&D and market development. Excluding the impact of foreign-exchange gains and losses, total profit in the first half increased approximately 8.79% year on year.

The company’s core businesses continued to expand. In the first half of 2026, revenue from medical imaging diagnosis and radiotherapy equipment was RMB 5.851 billion, up 19.66% year on year, while maintenance services revenue was RMB 980 million, up 20.11%. Overseas revenue reached RMB 1.765 billion, up 54.46% and accounting for 25.02% of total revenue; overseas service revenue rose 63.8% year on year. For full-year 2025, revenue was RMB 13.800 billion and net profit attributable to the parent was RMB 1.869 billion, representing year-on-year growth of 33.98% and 48.14%, respectively. This indicates that the recovery in domestic equipment replacement demand, overseas expansion and increasing sales of high-end products were the main growth drivers.

The company has a broad product portfolio covering MR, CT, XR, MI, ultrasound and radiotherapy. Through in-house development and production of core components, complete-system integration, software algorithms and maintenance services, it has established vertically integrated capabilities. Maintenance services carried a gross margin of 61.86%, higher than the 46.56% gross margin of equipment sales. However, equipment sales accounted for approximately 86.6% of core business revenue in 2025, while distribution revenue represented approximately 63.91%. The business therefore remains heavily dependent on equipment sales and distribution channels. Software revenue declined 34.49% in 2025 and 55.03% in the first half of 2026.

As of September 11, 2026, the company’s share price was RMB 103.11, with a TTM P/E of approximately 48x. Based on the consensus estimates of institutions, forward P/E for 2026–2028 was approximately 37.1x, 29.7x and 24.1x, respectively. The valuation already incorporates expectations for overseas growth, higher sales of high-end products, a recovery in domestic procurement and equipment replacement, and margin recovery. Technically, the share price was below the MA5, MA10 and MA20, while MACD remained below the zero line, indicating weak low-level short-term consolidation. RMB 101.3–102.0 represents important support, while RMB 104.5–106.1 is the main moving-average resistance zone.

2. Company Overview

2.1 Basic Information

2.2 Core Businesses and Product Portfolio

• MR magnetic resonance imaging systems
• CT X-ray computed tomography systems
• XR X-ray imaging systems, including fixed DR, mobile DR, mammography systems, C-arms and DSA
• MI molecular imaging systems, including PET/CT and PET/MR
• US color Doppler ultrasound diagnostic systems
• RT medical linear accelerators and integrated precision radiotherapy products
• Life-science instruments, including animal MR and animal PET/CT
• Maintenance services, software and digital solutions

2.3 Position in the Upstream and Downstream Value Chain and Cost/Profit Structure

United Imaging Healthcare operates in the midstream complete-machine and system-solutions segment of the high-end medical equipment value chain. It also extends upstream through in-house development and production of core components and downstream through software, algorithms, maintenance services and digital solutions, forming a vertically integrated model combining “in-house core components + complete-system integration + software algorithms + clinical applications.” The company has relatively high technology barriers and medium-to-high gross margins, but also undertakes substantial R&D, fixed-asset and working-capital investment.

• Key inputs purchased and used include superconducting wires, magnet materials, gradient-coil materials, radio-frequency components, electronic components and precision mechanical components for MR; X-ray tubes, detectors, high-voltage generators, flat-panel detectors, electronic components and gantry structural components for CT/XR; scintillation crystals, silicon photomultipliers, detector modules and electronic components for MI; accelerator tubes, multileaf collimators, power sources, modulators, treatment couches and onboard imaging systems for RT; as well as general-purpose chips, mechanical components, cooling and heat-dissipation components, software and computing platforms.
• In 2025, direct material costs for the medical-device business were RMB 5.991 billion, accounting for 88.65% of total medical-device costs; direct labor costs were RMB 189 million, or 2.80%; and manufacturing overhead was RMB 578 million, or 8.55%. Direct material costs for the equipment business were RMB 5.486 billion, accounting for 81.17% of equipment-business costs, indicating a cost structure heavily weighted toward materials and core components.
• The company has strong in-house R&D and production capabilities for core components, including MR superconducting magnets, gradient coils, gradient power amplifiers, RF power amplifiers, spectrometers and RF coils; CT detectors, X-ray tubes, high-voltage generators and image-reconstruction algorithms; PET scintillation crystals and digital detectors; RT accelerator tubes and multileaf collimators; and ultrasound probes and imaging algorithms.
• The annual report states that the company has mastered high-field human superconducting-magnet technology at 5.0T and above, as well as SiC gradient power-amplifier technology. It also has R&D capabilities for key components such as PET detectors, CT X-ray tubes and high-voltage generators. In-house production helps reduce external dependence, although the specific self-production ratio was not disclosed in the meeting materials.
• As of the end of 2025, purchases from the five largest suppliers totaled RMB 1.510 billion, representing 15.00% of total annual purchases; the largest single supplier accounted for 3.43%. All five largest suppliers were unrelated parties. The data refer to year-end 2025, and supplier names were anonymized, making it impossible to determine whether key materials were concentrated among a small number of specific vendors.
• The company has some scale-based purchasing and supplier bargaining power for general electronic components, mechanical parts and certain standardized components. For high-technology components such as superconducting magnets, detectors, X-ray tubes and scintillation crystals, bargaining power depends on the self-production ratio, procurement scale and technical barriers of the materials. The company should not be regarded as having strong pricing power over all upstream inputs.
• Downstream customers mainly include public and private hospitals, medical centers, oncology hospitals, nuclear medicine centers, research institutes and universities, overseas medical institutions and local distributors, as well as certain regional healthcare-service and equipment-procurement platforms.
• Sales to the five largest customers in 2025 totaled RMB 1.208 billion, or 8.75% of annual sales; the largest customer accounted for 3.91%. The data refer to 2025, and the concentration of the five largest customers was relatively low. Because some customer names were anonymized for commercial-confidentiality reasons, their types and regional distribution cannot be fully determined.
• High-end medical imaging equipment features high unit prices, long validation cycles and significant clinical dependence. Hospital procurement generally involves budgeting, tendering, configuration permits, installation and acceptance, and clinical-use validation. Brand, clinical references, after-sales service and equipment reliability influence customer decisions.
• Distribution revenue accounted for approximately 63.91% of core business revenue. Distributors play an important role in regional coverage, tendering and maintaining hospital relationships. The distribution model expands sales coverage but may reduce some end-market prices and gross margins while increasing channel-management and collection risks.
• Medical-equipment procurement is affected by policy and cycles. Configuration permits for large medical equipment, hospital capital expenditure, equipment-replacement policies and tendering schedules affect order confirmation and revenue recognition. The decline in 2024 revenue was related to the pace of implementation of domestic equipment-replacement policies, while domestic demand recovered in 2025 as these policies became more normalized.
• Maintenance services revenue was RMB 1.708 billion in 2025, with a gross margin of 61.86%, higher than the 46.56% gross margin of equipment sales. As the installed base expands, customers become more dependent on original-equipment-manufacturer maintenance, spare parts, software upgrades and application support. Maintenance services have therefore become an important source of monetization of the installed base and customer stickiness.
• As of December 31, 2025, accounts receivable stood at RMB 5.590 billion, approximately 40.51% of operating revenue and 2.99x 2025 net profit attributable to the parent, up 28.25% from the end of 2024. Net cash flow from operating activities was RMB 2.679 billion, compared with an outflow of RMB 619 million in 2024. Prepayments were RMB 264 million, up 34.92% year on year, mainly due to increased prepayments for raw-material purchases and strategic inventory building. Contract liabilities were RMB 2.975 billion, up 39.07%, mainly due to increased advance receipts for product sales and services. These figures indicate that sales expansion has involved significant accounts-receivable funding, although collections improved from 2024. Public data cannot determine the funding period of specific projects.
• The five largest suppliers accounted for 15.00% of purchases in 2025, with the largest single supplier accounting for 3.43%; the five largest customers accounted for 8.75% of sales, with the largest customer accounting for 3.91%. These concentration figures all refer to 2025. Supplier and certain customer names were anonymized, preventing further cross-checking of the actual concentration of key materials or customer types. The latest annual report should prevail.

The company operates in the midstream complete-machine and system-solutions segment of the high-end medical equipment value chain, while extending upstream into core components and downstream into maintenance services, software and digital solutions. It is a high-end equipment manufacturer with relatively strong technology and product capabilities but a cash-settlement side that still requires management. Further margin improvement will mainly depend on increasing the contribution of high-end MR, MI and RT products; reducing costs through in-house development and production of core components; increasing the proportion of overseas direct sales and high-end customers; expanding maintenance services as the installed base grows; achieving scale effects after capacity expansion; and reducing the adverse impact of the high distribution-model share on end-market prices and gross margins.

3. Financial Data and Valuation Analysis

3.1 Recent Operating Performance

The latest financial report is United Imaging Healthcare’s 2026 interim report, covering January 1 to June 30, 2026, and disclosed on August 19–20, 2026. Non-GAAP net profit attributable to the parent in the first half of 2026 was RMB 827 million, down 14.38% year on year; basic EPS was RMB 1.10, down 9.09%. Net cash flow from operating activities was negative RMB 242 million, compared with RMB 49 million in the same period of the previous year.

In the first half of 2026, the company delivered revenue growth but came under profit pressure. Gross margin was approximately 47.18%, down approximately 0.75 percentage points year on year. R&D expenses were RMB 1.011 billion, up 31.86%, with an R&D expense ratio of 14.33%; selling expenses were RMB 1.045 billion, up 11.41%. The decline in profit was mainly affected by foreign-exchange gains and losses: the company incurred approximately RMB 118 million in foreign-exchange losses in the first half of 2026, compared with approximately RMB 15 million in foreign-exchange gains in the same period of 2025. Excluding foreign-exchange gains and losses, total profit in the first half of 2026 increased approximately 8.79% year on year. By business, revenue from medical imaging diagnosis and radiotherapy equipment was RMB 5.851 billion, up 19.66%; maintenance services revenue was RMB 980 million, up 20.11%; software revenue was approximately RMB 13 million, down 55.03%; and overseas revenue was RMB 1.765 billion, up 54.46%, increasing to 25.02% of total revenue.

3.2 Earnings Forecasts

As of September 13, 2026, the Tonghuashun F10 platform showed that 29 institutions had forecast United Imaging Healthcare’s 2026 results over the preceding six months. Revenue forecasts for 2026–2028 were approximately RMB 16.079–16.981 billion, RMB 18.405–21.200 billion and RMB 21.114–26.819 billion, respectively. Forecast net profit attributable to the parent was approximately RMB 1.993–2.620 billion, RMB 2.495–3.354 billion and RMB 2.938–4.389 billion, respectively. EPS forecasts were approximately RMB 2.42–3.18, RMB 3.03–4.07 and RMB 3.56–5.33, respectively. These figures are aggregated sell-side research forecasts and publicly available research reports and do not constitute company guidance.

3.3 Valuation and Institutional Ratings

As of the September 11, 2026 close, United Imaging Healthcare’s share price was RMB 103.11, with a total market capitalization of approximately RMB 84.979 billion and approximately 824 million shares outstanding. The 52-week price range was approximately RMB 95.90–159.06. Yahoo Finance showed TTM EPS of approximately RMB 2.17 and a TTM P/E of approximately 47.52x. CFi.cn showed a dynamic P/E of approximately 48.06x, a P/E excluding non-recurring items of approximately 52.10x and a P/B of approximately 3.86x. Because earnings definitions, treatment of repurchased shares and data-update times differ across platforms, the current TTM P/E should be understood as approximately 48x. Based on consensus EPS, forward P/E for 2026–2028 was approximately 37.1x, 29.7x and 24.1x, respectively. Based on the earnings forecast ranges, forward P/E was approximately 32x–43x, 25x–34x and 19x–29x, respectively. Overall, the company’s current valuation falls within a high-growth-expectations pricing range rather than a low-valuation range. It incorporates expectations for continued overseas growth, higher sales of high-end products, recovery in domestic medical-equipment replacement and procurement demand, growth in maintenance services, conversion of R&D investment into results, and premiums associated with domestic substitution and internationalization. The sustainability of the valuation will depend on overseas revenue growth, recovery in domestic procurement, reduced foreign-exchange disruption and margin recovery. Key risks include exchange-rate volatility, slower-than-expected recovery in domestic procurement, overseas investment causing margins to fall short of expectations, and downward earnings revisions in the context of a high valuation.

4. Recent News and Announcements

4.1 Share Repurchase Continues and Price Ceiling Adjusted

On September 2, 2026, the company disclosed a progress announcement on its share repurchase. As of the announcement, approximately 2.624 million shares had been repurchased for a cumulative consideration of approximately RMB 283 million, at an average price of approximately RMB 107.96 per share. The repurchase plan has a total funding amount of no less than RMB 300 million and no more than RMB 600 million. The repurchase period runs from April 20, 2026 to April 19, 2027. The repurchased shares will be used for an employee share-ownership plan or equity incentives and will not be cancelled. Due to the implementation of the 2026 interim cash dividend, the company adjusted the repurchase price ceiling from RMB 139.82 per share to RMB 139.69 per share on September 3, effective from the ex-dividend date of September 9, 2026. The company has not disclosed any termination of the repurchase, material change in its purpose or failure of the repurchase plan.

4.2 2026 Interim Cash Dividend Implemented

The company’s 2026 interim profit-distribution plan provides for a cash dividend of RMB 0.13 per share, with no bonus shares and no capitalization of capital reserves. The record date was September 8, 2026, and both the ex-dividend date and cash-dividend payment date were September 9, 2026. The company had total share capital of 824,157,988 shares. After deducting the 6,758,348 shares held in the repurchase account, the share capital participating in the distribution was 817,399,640 shares, implying a total cash dividend of approximately RMB 106.26 million. Following implementation of the dividend, the company simultaneously lowered the repurchase-price ceiling.

4.3 2026 Interim Results Presentation Held

The company held its 2026 interim results presentation via the SSE Roadshow Center from 16:00 to 17:00 on September 9, 2026. In the first half of 2026, the company generated operating revenue of approximately RMB 7.052 billion, up 17.22% year on year, and net profit attributable to shareholders of the listed company of approximately RMB 897 million, down 10.12%. The company stated that the decline in profit was mainly attributable to foreign-exchange gains and losses, as well as increased investment in global operations, R&D and market expansion. Foreign-exchange losses were approximately RMB 118 million during the reporting period, compared with foreign-exchange gains of approximately RMB 15 million in the same period of the previous year. Service revenue in the first half was approximately RMB 980 million, up 20.11%, with overseas service revenue increasing 63.8% year on year. As of this search, no formal earnings guidance for the first three quarters or full year of 2026 had been identified.

4.4 Internal Investment Structure Adjustment and Delay of Informationization Project

On September 1, 2026, the company disclosed an announcement regarding the adjustment of the internal investment structure of certain projects funded by raised capital and project delays. The company plans to adjust the internal investment structure of the “Next-Generation Product R&D Project” and extend the scheduled completion date of the “Informationization Enhancement Project” from September 2026 to September 2027. The adjustment does not change the project implementation entity or the total amount of raised funds invested, and does not constitute a change in the use of raised funds. The sponsors, CITIC Securities and China International Capital Corporation, expressed no objection.

4.5 First Grant Under 2025 Restricted Stock Incentive Plan Enters First Vesting Period

On September 1, 2026, the company disclosed announcements regarding the fulfillment of vesting conditions for the first vesting period of the initial grant under its 2025 restricted stock incentive plan, the cancellation of certain granted but unvested restricted shares, and related adjustments. The plan has entered implementation of its first vesting period, and some unvested shares have been cancelled. Because the full text of all relevant announcements could not be reliably obtained during this search, the specific number of eligible employees, vesting quantity and cancelled quantity remain uncertain and are not cited definitively.

4.6 No New Major-Shareholder Selling, Buying or Ownership-Change Announcements Identified

As of September 13, 2026, a search of announcements since September 2026 identified no new selling plans, buying plans or ownership-change announcements issued by the company’s controlling shareholder, actual controller or shareholders holding more than 5%. The company’s 2026 interim report shows that the employee share-ownership platform made no sales during the reporting period as of June 30, 2026. A selling plan disclosed by the employee share-ownership platform in 2025 was a historical matter and is not regarded as a new shareholder development in September 2026.

4.7 Overall Stability of Top-10 Shareholder Structure

Public shareholder data as of June 2026 indicate that the shareholding percentages of major shareholders, including United Imaging Healthcare Technology Group Co., Ltd., Shanghai Lianhe Investment Co., Ltd. and Shanghai Yingsheng Investment Partnership, were generally stable. Holdings by Hong Kong Securities Clearing Company Limited and healthcare ETFs under Bank of China showed modest increases or decreases. These changes mainly came from periodic reports or publicly available tradable-shareholder data and do not constitute ownership-change disclosures triggered by shareholders holding more than 5%.

4.8 No Major New M&A, Restructuring or Regulatory Penalties Identified

As of September 13, 2026, no announcements were identified indicating that the company had initiated a major asset restructuring, major acquisition, asset purchase or asset sale in September 2026. No new regulatory work letters, disciplinary actions, warning letters or investigation announcements issued by the Shanghai Stock Exchange or securities regulators against the company were identified.

4.9 Maintenance-Service Contract Won from Jiangyou 903 Hospital

Public government-procurement information indicates that Shanghai United Imaging Healthcare Co., Ltd. won the United Imaging equipment maintenance-service project for Jiangyou 903 Hospital on September 9, 2026, with a contract value of approximately RMB 82.5 million. The information came from government-procurement results and citations by financial media. This search did not identify a separate disclosure by the company regarding a material contract, so it cannot yet be determined whether the contract meets the listed company’s material-contract disclosure standard or what specific impact it will have on 2026 revenue and profit.

4.10 Industry Procurement Environment and Second-Half Demand Outlook

In its interim report and investor communications, the company stated that the allocation of equipment-replacement funds, the advancement of local procurement projects and the implementation of centralized procurement projects should support recovery in domestic demand during the second half. These comments represent management’s assessment of the operating environment and do not mean that the company has received specific policy subsidies or secured confirmed orders.

5. Share-Price Performance and Technical Analysis

5.1 Price Overview

5.2 Technical Indicators

As of the September 11, 2026 close, United Imaging Healthcare exhibited weak low-level consolidation, with a short-term rebound but no trend reversal. The share price was below MA5, MA10 and MA20, indicating a weak moving-average system. MACD was below the zero line, with DIF below DEA, and daily momentum remained bearish. RSI was weak but not extremely oversold. The share price was between the lower and middle Bollinger Bands; RMB 102 represented important short-term support, while approximately RMB 106 was the first resistance level. The share-price rise on September 11 was accompanied by net institutional outflows, so the rebound lacked synchronized confirmation from large and extra-large orders. Although concentration among the top-10 tradable shareholders was high, the data were as of March 31, 2026, while shareholder-count data were as of June 30, 2026, creating quarterly or periodic lags. Recent daily turnover was generally below 1%, so short-term breakouts or breakdowns should be confirmed through both trading value and turnover.

5.3 Short-Term Outlook (Next Week; Scenario Analysis for Reference Only)

⚠️ Risk warning: The following content is a subjective scenario analysis based on closing data as of September 11, 2026. It does not constitute investment advice and does not represent a definitive judgment regarding the future direction or price of the stock.

① Key Technical Levels

② Scenarios for the Next Week (Subjective Weightings, Not Statistical Probabilities)

• Range-bound consolidation (relatively higher subjective heuristic weighting, approximately 60%; not a statistical probability): price range of approximately RMB 101.5–106.0. The trigger would be the share price holding RMB 101.3–102.0 without breaking above RMB 106 on increased volume. Based on the share price being between the lower and middle Bollinger Bands, RSI not being extremely oversold, trading value remaining within the normal range and the absence of sustained one-way institutional outflows over the past 10 days, the stock is more likely to show repeated low-level consolidation than a clear trend reversal
• Weak decline (medium subjective heuristic weighting; not a statistical probability): price range of approximately RMB 96.0–101.5. Triggers include a decisive closing-price break below RMB 101.3–102.0 accompanied by trading value materially exceeding the recent normal range of RMB 300–500 million, or relatively large and consecutive institutional net outflows. If this support zone fails, the next observation area is the historical low around RMB 95.6–96.0
• Stronger rebound (low subjective heuristic weighting; not a statistical probability): price range of approximately RMB 106.0–110.0. Triggers include a high-volume move above MA20 at approximately RMB 106.09, followed by a break above the recent resistance area of RMB 108.5–109.8. Institutional funds would also need to shift from net outflows to consecutive net inflows, accompanied by trading value materially above the recent midpoint. A low-volume rebound to approximately RMB 105–106 would likely remain constrained by the moving averages and should not be regarded as confirmation of a trend reversal

③ Capital and Liquidity Background

As of September 11, 2026, daily turnover was 0.53% and trading value was approximately RMB 450 million. Five-day turnover was approximately 4.92%, 10-day turnover approximately 9.27%, and trading value over the past 20 trading days approximately RMB 266–796 million, with most sessions at approximately RMB 300–500 million. The top-10 tradable shareholders held approximately 60.70% in aggregate as of March 31, 2026, while shareholder count was approximately 40,400 as of June 30, 2026. Both figures may differ from the current actual structure. The top-10 tradable shareholders mainly comprise company shareholders, investment companies, partnerships and individuals. Identifiable institutional holdings, including public ETFs and Stock Connect holdings, totaled approximately 4.19%, indicating a relatively low institutional holding ratio. The actual tradable float does not equal total tradable shares, and daily turnover is generally below 1%. Therefore, any rapid breakout or breakdown should be confirmed through both trading value and turnover. The validity of short-term price signals is relatively limited during periods of low activity.

A volume-confirmation signal to monitor is the following: if daily trading value subsequently expands to approximately RMB 700–800 million or more for consecutive sessions, turnover rises to approximately 0.9%–1.0% or higher, and the closing price remains above RMB 106, this could confirm a material increase in short-term capital participation. If trading value remains below the recent normal midpoint of RMB 300–500 million throughout the rebound, the sustainability of the rebound would remain uncertain.

④ Key Points to Monitor (Observation Framework Only, Not Trading Instructions)

• Monitor whether the RMB 101.3–102.0 support zone holds. If it fails, continue to monitor the historical low zone of RMB 95.6–96.0.
• Monitor whether the closing price can decisively break above the moving-average resistance zone of RMB 104.5–106.1.
• Monitor whether trading value reaches approximately RMB 700–800 million or more for consecutive sessions during a breakout and whether turnover rises to approximately 0.9%–1.0% or more.
• Monitor whether institutional funds shift from recent net outflows to consecutive net inflows. All of the above are observation frameworks, not trading instructions.

The above scenario analysis is based on closing data as of September 11, 2026, historical prices and technical-indicator calculations. Short-term share prices may also be affected by news, capital flows, broader-market conditions and other factors. Technical indicators have inherent lags and limitations. This analysis does not guarantee actual future performance and does not constitute a buy or sell recommendation. Investors should independently assess the latest market information and bear investment risks themselves.

6. Industry Landscape and Competitor Analysis

6.1 Industry Overview

According to the company’s annual report, United Imaging Healthcare operates in the manufacture of medical instruments and apparatus within the special-purpose equipment manufacturing industry, specifically medical diagnosis, monitoring and treatment equipment. Medical imaging equipment is a high-technology segment of the medical-device industry involving biomedical engineering, mechanics, electronics, materials, algorithms, software and clinical applications.

6.2 Competitive Landscape

• The first tier of global competitors includes GE HealthCare, Siemens Healthineers and Philips Healthcare. These companies have long-established brand, clinical, channel and global-service advantages and are highly competitive in high-end hospitals and overseas markets.
• The second tier of domestic competitors includes United Imaging Healthcare, Neusoft Medical, Wandong Medical and Mindray, as well as other integrated or multi-product-line manufacturers. United Imaging focuses on high-end medical imaging, molecular imaging and radiotherapy; Mindray is stronger in patient monitoring and life support, in vitro diagnostics and ultrasound; while Neusoft Medical and Wandong Medical have differentiated portfolios in CT, MR, XR and DSA.
• The third tier comprises companies focused on specific segments, including radiotherapy-equipment manufacturers such as Elekta, as well as specialist companies in specific imaging equipment, ultrasound, interventional imaging and core components.
• The company’s 2025 annual report identifies GE HealthCare, Siemens Healthineers, Philips Healthcare, Elekta, Wandong Medical and Neusoft Medical as major comparable companies, and also lists Mindray as a domestic competitor.
• According to the company’s annual report and disclosure methodology, United Imaging Healthcare ranked first in China’s 1.5T-and-below superconducting MR market, second in the 3.0T MR market and first in the above-3.0T ultra-high-field MR market. Based on domestic incremental market value in 2025, PET/CT ranked first in China for the tenth consecutive year, while PET/MR ranked first in China. XR diagnostic products ranked second by market share. RT ranked first for the first time in China’s incremental radiotherapy-equipment market in 2025. CT maintained a leading position in the Chinese market.
• The above rankings are mainly based on CIC data cited in the company’s annual report and the company’s own disclosure methodology. Some use annual incremental market value rather than the entire installed-base market, and statistical definitions may differ across product lines. The rankings therefore cannot simply be interpreted as a unified market share for the entire medical imaging industry.

6.3 Major Competitors

United Imaging Healthcare’s main competitive strengths lie in its high-end medical imaging, molecular imaging and radiotherapy portfolios; its in-house development and production of core components; and its capabilities in complete-system integration, software algorithms and clinical applications. It has established strong positions in certain MR, PET/CT, PET/MR, XR and RT subsegments. Compared with global leaders, the company still trails in global brand recognition, clinical accumulation, overseas channels and service networks. Compared with domestic manufacturers, it is more focused on high-end imaging, molecular imaging and radiotherapy. Industry growth is affected by hospital capital expenditure, configuration permits for large medical equipment, equipment-replacement policies and tendering cycles. The company also faces uncertainty related to overseas regulatory approvals, trade frictions, exchange rates and investment in localized services.

7. Risk Factors

• Domestic procurement of large medical equipment is heavily influenced by hospital capital expenditure, configuration permits, the allocation of equipment-replacement funds and tendering schedules. Domestic equipment demand in 2025 was affected by the pace of equipment-replacement policy implementation. If local procurement or centralized procurement progresses more slowly than the company expects, equipment revenue recognition and profit release may fall short of expectations.
• The company incurred approximately RMB 118 million in foreign-exchange losses in the first half of 2026, compared with foreign-exchange gains of approximately RMB 15 million in the same period of the previous year. Overseas revenue had increased to RMB 1.765 billion, or 25.02% of total revenue. As overseas operations expand, exchange-rate fluctuations may continue to cause volatility in total profit and net profit attributable to the parent.
• Distribution revenue was RMB 8.406 billion in 2025, accounting for approximately 63.91% of core business revenue. Although the distribution model helps expand regional coverage, it may pressure end-market prices and gross margins while increasing channel-management and collection risks. As of the end of 2025, accounts receivable were RMB 5.590 billion, approximately 40.51% of operating revenue, up 28.25% year on year.
• The company’s medical-device costs are heavily dependent on materials and core components. Direct material costs accounted for 88.65% of total medical-device costs in 2025, while direct material costs accounted for 81.17% of equipment-business costs. If the costs of superconducting magnets, detectors, X-ray tubes, scintillation crystals and other components rise, or if the self-production ratio and cost-reduction results fall short of expectations, gross margins may be compressed.
• R&D expenses were RMB 1.011 billion in the first half of 2026, up 31.86%, with an R&D expense ratio of 14.33%; selling expenses also increased 11.41%. Increased investment in global operations, R&D and market expansion has already pressured profit. If investment in high-end product R&D, overseas approvals and localized services does not translate into revenue in a timely manner, profitability may fall below expectations.
• Software revenue is relatively small and continues to decline, falling 34.49% year on year in 2025 and reaching approximately RMB 13 million in the first half of 2026, down 55.03%. If software and digital solutions do not improve, the company’s dependence on equipment sales will remain difficult to reduce materially.
• The company faces competition from global leaders such as GE HealthCare, Siemens Healthineers and Philips Healthcare in brand recognition, clinical experience, overseas channels and service networks, as well as competition from domestic and specialist companies such as Neusoft Medical, Wandong Medical and Elekta. Overseas markets also involve uncertainty relating to regulatory approvals, trade frictions and localized-service investment.
• As of September 11, 2026, the company’s TTM P/E was approximately 48x, placing the valuation in a high-growth-expectations pricing range. If overseas revenue growth, domestic procurement recovery, mitigation of foreign-exchange disruption or margin recovery falls short of expectations, institutional earnings forecasts may be revised downward and the valuation may come under pressure. Technically, the share price was below the major short-term moving averages. If RMB 101.3–102.0 support fails, the share price may further test the historical low area of RMB 95.6–96.0.

8. Conclusion and Outlook

United Imaging Healthcare’s medium-term growth drivers mainly comprise higher sales of high-end MR, MI and RT products; recovery in domestic medical-equipment replacement and procurement demand; expansion of overseas revenue and service businesses; and growth in maintenance services driven by the expanding installed base. The company has strong competitive positions in certain MR, PET/CT, PET/MR, XR and RT subsegments, while its in-house development and production of core components provides a foundation for product differentiation and cost improvement. Institutional average forecasts for 2026–2028 revenue and net profit attributable to the parent are RMB 16.635 billion, RMB 20.063 billion and RMB 24.066 billion, and RMB 2.291 billion, RMB 2.859 billion and RMB 3.530 billion, respectively. These forecasts do not constitute company guidance.

In the short term, revenue growth has not yet fully translated into profit growth. Foreign-exchange volatility, R&D investment and global operating costs may continue to affect earnings. Gross margin was approximately 47.18% in the first half of 2026, down approximately 0.75 percentage points year on year, while operating cash flow also turned negative. Future earnings improvement will depend on the quality of overseas growth, recovery in domestic procurement, end-market pricing and collections under the distribution model, cost reductions for core components, and conversion of R&D investment into revenue and profit.

The company has advanced its share repurchase and implemented an interim cash dividend, while extending the informationization-enhancement project to September 2027, indicating that capital-management and project-construction initiatives remain ongoing. With the current TTM P/E of approximately 48x, the market already has high expectations for future growth and profit recovery. If earnings are delivered more slowly than expected, valuation digestion pressure may increase. Technically, if the share price cannot decisively hold above approximately RMB 106, weak consolidation may continue. If RMB 101.3–102.0 support breaks, attention should turn to the risk of a move toward the historical low area of RMB 95.6–96.0.

Data Sources

• United Imaging Healthcare (688271)_Company Announcements_United Imaging Healthcare: 2025 Annual Report_Sina Finance_Sina.com
• Shanghai United Imaging Healthcare Co., Ltd. 2024 Annual Report
• United Imaging Healthcare (688271)_Company Announcements_United Imaging Healthcare: Summary of 2025 Annual Report_Sina Finance_Sina.com
• United Imaging Healthcare (688271)_Company Announcements_United Imaging Healthcare: 2026 Interim Report_Sina Finance_Sina.com
• United Imaging Healthcare (688271) 2026 Interim Results Review: Rapid Overseas Expansion and Accelerating High-End Product Sales; Foreign-Exchange Disruption Pressures Short-Term Profit_Sina Finance_Sina.com
• United Imaging Healthcare (688271) Earnings Forecasts_F10_Tonghuashun Financial Services
• United Imaging Healthcare (688271) 2025 Annual Report and 2026 First-Quarter Results Review: Significant Strategic Results Highlight Leadership Position_Sina Finance_Sina.com
• Research Report Indicator Digest—Research Reports—Stock Channel—Securities Star
• September 2, 2025
• 174 Stocks Receive Buy Ratings; Latest: GigaDevice—CFi.CN
• United Imaging Healthcare (688271.SS) Chart—Yahoo Finance
• Latest Announcements
• United Imaging Healthcare (688271)_Company Announcements_United Imaging Healthcare: Announcement on Adjusting the Repurchase Price Ceiling Following Implementation of the 2026 Interim Equity Distribution_Sina Finance_Sina.com
• United Imaging Healthcare (688271)_Company Announcements_United Imaging Healthcare: Announcement on Implementation of the 2026 Interim Equity Distribution_Sina Finance_Sina.com
• United Imaging Healthcare (688271)_Company Announcements_United Imaging Healthcare: Announcement on Convening the 2026 Interim Results Presentation_Sina Finance_Sina.com
• United Imaging Healthcare (688271)_Company Announcements_United Imaging Healthcare: Investor Relations Activity Record_United Imaging Healthcare_2026-002_Sina Finance_Sina.com
• United Imaging Healthcare (688271)_Company Announcements_United Imaging Healthcare: Announcement on Adjusting the Internal Investment Structure of Certain Projects Funded by Raised Capital and Project Delays_Sina Finance_Sina.com
• United Imaging Healthcare (688271) Company Announcements_Sina Finance_Sina.com
• United Imaging Healthcare (688271)_Company Announcements_United Imaging Healthcare: 2026 Interim Report_Sina Finance_Sina.com
• United Imaging Healthcare (688271)_Company Announcements_United Imaging Healthcare: Shareholder Share-Reduction Plan Announcement_Sina Finance_Sina.com
• United Imaging Healthcare (688271) Stock Price, Market Data, News and Financials_Sina Finance_Sina.com
• Jiangyou Government Procurement Contract Announcement_Government Procurement Contract Announcement
• United Imaging Healthcare (688271)_Stock Quotes, Market Overview_CFi.cn
• United Imaging Healthcare (688271)_Stock Quotes, Market Overview_CFi.cn
• United Imaging Healthcare (688271)_Stock Quotes—Sohu Securities
• Shanghai United Imaging Healthcare Technical Analysis (688271)—Investing.com
• United Imaging Healthcare (688271.SH) Stock Quotes, Historical Data and Institutional Fund Flow—Dawave Data
• United Imaging Healthcare (688271) Historical Data: Historical Quotes, Prices and Charts—Investing.com

This report was automatically searched, compiled and generated by AI based on publicly available information. Information is current as of the September 11, 2026 close; technical indicators, fund flows and market data primarily use that date as the cutoff, while top-10 tradable shareholder data are as of March 31, 2026 and shareholder-count data are as of June 30, 2026. Timing differences may exist. Specific data should be verified against the company’s formal announcements and authoritative data terminals. This report is for information and research reference only and does not constitute investment advice. Investors should make independent judgments and bear investment risks themselves.